BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21084261)

  • 1. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.
    Mohammed A; Janakiram NB; Li Q; Madka V; Ely M; Lightfoot S; Crawford H; Steele VE; Rao CV
    Cancer Prev Res (Phila); 2010 Nov; 3(11):1417-26. PubMed ID: 21084261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
    Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
    Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice.
    Mohammed A; Janakiram NB; Brewer M; Duff A; Lightfoot S; Brush RS; Anderson RE; Rao CV
    Neoplasia; 2012 Dec; 14(12):1249-59. PubMed ID: 23308056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
    He P; Yang JW; Yang VW; Bialkowska AB
    Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
    Rao CV; Mohammed A; Janakiram NB; Li Q; Ritchie RL; Lightfoot S; Vibhudutta A; Steele VE
    Neoplasia; 2012 Sep; 14(9):778-87. PubMed ID: 23019409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.
    Fendrich V; Jendryschek F; Beeck S; Albers M; Lauth M; Esni F; Heeger K; Dengler J; Slater EP; Holler JPN; Baier A; Bartsch DK; Waldmann J
    Oncogene; 2018 Apr; 37(14):1845-1856. PubMed ID: 29367759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice.
    Bai H; Li H; Zhang W; Matkowskyj KA; Liao J; Srivastava SK; Yang GY
    Carcinogenesis; 2011 Nov; 32(11):1689-96. PubMed ID: 21859833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.
    Funahashi H; Satake M; Dawson D; Huynh NA; Reber HA; Hines OJ; Eibl G
    Cancer Res; 2007 Aug; 67(15):7068-71. PubMed ID: 17652141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.
    Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L
    Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.
    Philip B; Roland CL; Daniluk J; Liu Y; Chatterjee D; Gomez SB; Ji B; Huang H; Wang H; Fleming JB; Logsdon CD; Cruz-Monserrate Z
    Gastroenterology; 2013 Dec; 145(6):1449-58. PubMed ID: 23958541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.
    Mohammed A; Janakiram NB; Suen C; Stratton N; Lightfoot S; Singh A; Pathuri G; Ritchie R; Madka V; Rao CV
    Mol Carcinog; 2019 Oct; 58(10):1908-1918. PubMed ID: 31313401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.
    DiNorcia J; Lee MK; Moroziewicz DN; Winner M; Suman P; Bao F; Remotti HE; Zou YS; Yan SF; Qiu W; Su GH; Schmidt AM; Allendorf JD
    J Gastrointest Surg; 2012 Jan; 16(1):104-12; discussion 112. PubMed ID: 22052106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
    Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
    Chang HH; Moro A; Chou CEN; Dawson DW; French S; Schmidt AI; Sinnett-Smith J; Hao F; Hines OJ; Eibl G; Rozengurt E
    Sci Rep; 2018 Apr; 8(1):5899. PubMed ID: 29651002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
    Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
    Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer.
    Waldmann J; Fendrich V; Reichert M; Hecker A; Bartsch DK; Padberg W; Holler JPN
    J Surg Res; 2018 Mar; 223():230-236. PubMed ID: 29433879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
    Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
    Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
    Rao CV; Janakiram NB; Madka V; Devarkonda V; Brewer M; Biddick L; Lightfoot S; Steele VE; Mohammed A
    Oncotarget; 2015 Oct; 6(32):33290-305. PubMed ID: 26429877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.
    Mohammed A; Janakiram NB; Madka V; Pathuri G; Li Q; Ritchie R; Biddick L; Kutche H; Zhang Y; Singh A; Gali H; Lightfoot S; Steele VE; Suen CS; Rao CV
    Oncotarget; 2017 Nov; 8(58):97822-97834. PubMed ID: 29228654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
    Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
    J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.